GDI1 and metabolic disease: Thetreatment of HFD with PSP enhanced energy expenditure and exhibitedthe prevention of HFD-induced metabolic disorders.23 Our study corroborated these findings in treating the obeseanimals, as PSP supplementation significantly increased FNDC5 andPGC-1α protein expression in both subcutaneous and visceralfat, with a marked increase in UCP-1 expression in visceral fat.